This is the RSS news feed of one of our preset news channels on LSIS - The Life Science Infromation Service. Please visit us to find a current view of this one and many more channels via our alerting push services: http://www.lsis.com/channels/?query=4 http://www.lsis.com/goto/r4/rss 2012-02-04T11:10:06+01:00 text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 DARMSTADT, Germany, Feb 03, 2012 (BUSINESS WIRE) - -Deal provides Threshold with an upfront payment of EUR 19 million ($25 million), plus further potential milestones and royalties as well as an option to co-commercialize in the United States Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 MENLO PARK, Calif., Feb. 2, 2012 /PRNewswire via COMTEX/ - Auxogyn, Inc., a privately-held company focused on advancing women's reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures. "Over the course of the last year, we have executed an aggressive operating (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8105816 |-| Title: Nucleic acid molecules encoding BANK1 splice variants |-| Inventors: Abderrahim; Hadi (Divonne les Bains, FR), Kozyrev; Sergei V. (Uppsala, SE) |-| Assignee: Merck Serono S. A. (Coinsins, Vaud, CH) |-| The present invention relates to a new splice variant of BANK1, the use of SNPs in BANK1 for diagnostics and the use of antagonists to modulate BANK1 and/or the BANK1 pathway. text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8106214 |-| Title: 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors |-| Inventors: Rueckle; Thomas (Plan-les-Ouates, CH), Shaw; Jeffrey (Vessy, CH), Church; Dennis (Commugny, CH), Covini; David (Neydens, FR) |-| Assignee: Merck Serono SA (Coinsins, CH) |-| The present invention is related to 2-imino-azolinone-vinyl fused-benzene derivatives of Formula (1) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 LONDON-(Marketwire - January 30, 2012) - Based on its recent analysis of the infertility therapeutics market, Frost & Sullivan recognizes Merck Serono, the pharmaceutical division of Merck KGaA, Darmstadt, Germany, with the 2011 Europe Frost & Sullivan Award for Competitive Strategy Leadership. The European hormone products market for infertility has been relatively stagnant over a decade with less differentiation in terms of product characteristics and delivery mechanisms. Merck Serono, by (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 Strasbourg, France, January 30, 2012 - Domain Therapeutics announced today that it has been awarded a grant from The Michael J. Fox Foundation (http:/www.michaeljfox.org) for the optimization and pharmacological characterization of novel metabotropic glutamate receptor III (mGluR3) Positive Allosteric Modulators (PAMs) to treat Parkinson's disease (PD). The one-year grant of USD 300,000 was awarded under the Foundation's therapeutics development initiative aimed at supporting pre-clinical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 Treatment of multiple sclerosis (MS) with disease-modifying drugs (DMDs) can reduce relapse frequency and delay disability progression. Although adherence to DMDs is difficult to measure accurately, evidence suggests that poor adherence is common and can compromise treatment success. There are likely to be multiple factors underlying poor adherence. To better understand these factors, the global MS Choices Survey investigated patient and physician perspectives regarding key aspects of MS (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 Martinsried, Germany, January 25, 2012 / B3C newswire / Affectis Pharmaceuticals AG, a pharmaceutical company developing novel drugs for the treatment of neuroinflammatory diseases, announced today that the European Patent Office has granted a key patent for its oral brain-penetrant P2X7 antagonist AFC-5128 which is being developed for the treatment of neuropathic pain and multiple sclerosis. The European patent EP2105164 is related to the composition of AFC-5128, a highly potent orally active (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 (TAMPA, FLORIDA, USA, 23 January 2012) ISPE announced today that five pharmaceutical professionals were awarded Certified Pharmaceutical Industry Professional ¢ (CPIP ¢) credentials during the fourth quarter of 2011. This credential is given to experienced pharmaceutical technical professionals who meet the program s eligibility requirements and pass a rigorous exam covering product development, facilities and equipment, information systems, and other pertinent areas of pharmaceutical (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 Background:? Severity assessment of patients with psoriasis is a critical issue. Classical clinical assessment has been recently combined with quality of life (QoL) scores, but a number of instruments are used. Moreover, studies have focus on patients with moderate to severe psoriasis. Objectives:? To compare the characteristics of QoL instruments in patients with the full range of psoriasis severity attending dermatology clinics. Methods:? Observational, prospective, multicentre study. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 GHENT, BELGIUM-(Marketwire - January 10, 2012) - GHENT, Belgium, 10 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it has been granted an extended Certificate of Good Manufacturing Practice (GMP) from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium for its new GMP unit at its headquarters in Ghent, after having been inspected in November 2011. Having received this accreditation, Ablynx's GMP unit will now perform release- testing on Drug Substance (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8093010 |-| Title: Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer |-| Inventors: Imhof; Beat A. (Conches, CH), Aurrand-Lions; Michel (Marseilles, FR) |-| Assignee: Merck Serono S.A. (Coinsins, Vaud, CH) |-| The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 GHENT, BELGIUM-(Marketwire - January 09, 2012) - GHENT, Belgium, 9 January 2012 - Ablynx [Euronext Brussels: ABLX] today announced that it will present a review of its progress in 2011, together with an outline of the Company's evolving strategy and a review of its portfolio and priorities for 2012, at the 30(th) Annual J.P. Morgan Healthcare Conference in San Francisco, 9-12 January 2012. During the course of 2011, Ablynx has made significant progress both commercially and clinically. Cash (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 GHENT, BELGIUM-(Marketwire - January 04, 2012) - Ablynx [Euronext Brussels: ABLX] today announced that it plans to webcast its corporate presentation at the 30(th) Annual J.P. Morgan Healthcare Conference on Wednesday, 11 January 2012 at 03:30 p.m. PST / 00:30 a.m. CET. The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of the Ablynx website at www.ablynx.com. Shortly (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/channels/?query=4 ScienceDaily (Dec. 25, 2011) A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9. The results of their research recently appeared in Nature Medicine. See Also: Health & Medicine Immune (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 Nanosuspensions have gained great interest in the last decade as a formulation tool for poorly soluble drugs. By decreasing particle sizes nanosuspensions enhance dissolution rate and bioavailability of the active pharmaceutical ingredient. Micro-osmotic pumps are widely used in experimental pharmacology and offer a tool of interest for the sustained release of nanosuspensions via the intraperitoneal or subcutaneous application site. The purpose of the present study was to investigate in-vitro (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 New York, NY; Danvers, MA December 15, 2011 HCPro, the leading provider of integrated information, education, training, and consulting for the US healthcare regulatory and compliance markets, has purchased Luxid, the award-winning Semantic Content Enrichment software solution from TEMIS. HCPro will use the TEMIS software solution to speed the development of its new database and compliance products thanks to automated knowledge extraction from content. With Luxid, HCPro will also strengthen the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 GHENT, BELGIUM-(Marketwire - December 12, 2011) - Ablynx [Euronext Brussels: ABLX] and partner Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that they have advanced the Nanobody candidate, ALX-0761, into pre- clinical development for the treatment of autoimmune diseases. This is the first pre- clinical candidate that has emerged from the collaboration which the companies entered in 2008, and will result in a EUR1 million milestone payment to Ablynx. In September (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 Basel (Switzerland), Mannheim (Germany), December 13, 2011 / B3C newswire / VAXIMM AG, a Swiss-German biotech firm and Merck KGaA spin-off, announced today the start of the first clinical trial of its investigational oral therapeutic cancer vaccine VXM01. The placebo-controlled phase I dose escalation study intends to enroll up to 45 pancreatic cancer patients at the Heidelberg University Hospital (Heidelberg, Germany). In addition to standard-of-care treatment, the patients will receive (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8075894 |-| Title: Use of soluble CD164 in inflammatory and/or autoimmune disorders |-| Inventors: Chvatchko; Yolande (Confignon, CH) |-| Assignee: Merck Serono SA (Coinsins, Vaud, CH) |-| The present invention relates to novel therapeutic uses of soluble proteins comprising the extracellular region of human CD164, in particular for treating inflammatory and/or autoimmune disorders. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 BACKGROUND: In patients presenting with a first clinical demyelinating event that is suggestive of multiple sclerosis (MS), treatment with interferon beta can delay the occurrence of further attacks and the onset of MS. We investigated the effects of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event. METHODS: We undertook a multicentre phase 3 study (REbif FLEXible dosing in early MS [REFLEX]) that included patients (aged 18-50 (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8071375 |-| Title: Use of IL-6-type cytokines for maturation of oocytes |-| Inventors: Clark; Ann M. (Weymouth, MA), de Matos; Daniel Gustavo (Pembroke, MA), Jackson; Jennifer A. (Pembroke, MA), Palmer; Stephen S. (Plympton, MA), Tran; Cam Anh T. (Quincy, MA) |-| Assignee: Merck Serono SA (Coinsins, Vaud, CH) |-| The use of certain IL-6-type cytokines for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used in in vitro (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8071597 |-| Title: Pyrazine compounds and uses as PI3K inhibitors |-| Inventors: Gaillard; Pascale (Collonges Sous Sal{grave over ()}{grave over (})}ve, FR), Quattropani; Anna (Geneva, CH), Pomel; Vincent (Groisy, FR), Rueckle; Thomas (Geneva, CH), Klicic; Jasna (Geneva, CH), Church; Dennis (Commugny, CH) |-| Assignee: Merck Serono SA (Coinsins, Vaud, CH) |-| The present invention is related to pyrazine derivatives of Formula (I) in particular for the treatment and/or (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 In the present study, positively charged 1,2-dioleoyloxy-3-trimethylammoniumpropane (DOTAP) liposomes as a delivery system for a hydrophilic decapeptide were developed. The main objective was the preparation of a stable, highly loaded, lyophilised formulation to yield the basis for an acceptable shelf life. The influences of addition of cholesterol, pH value, amounts of lipid and peptide, type and amount of sugar-based cryoprotective agent (trehalose and sucrose), and time point for (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 The assessment of kidney damage is a challenge and must incorporate assessment of the functional capacity of the kidney, as well as a comprehensive understanding of the kidney's role. Multiple parameters have been used for many years to measure renal functionality to assess renal damage. It is astonishing that, beside histopathology, the most common traditional parameters are serum based. However, urine is also used to obtain additional information regarding the health status of the kidneys. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 Location (21 November 2011) BD Medical, a segment of BD (Becton, Dickinson and Company), announced today the launch of the BD Physioject ¢ disposable auto-injector. This clinically proven,* reliable and cost-effective system is specifically designed for self-injection of drugs by patients suffering from chronic diseases, including rheumatoid arthritis, multiple sclerosis, asthma and osteoporosis. The BD Physioject ¢ auto-injector presents key benefits for patients such as ease of use and (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 Targeting of the epidermal growth factor receptor (EGFR) with monoclonal antibodies has become an established antitumor strategy in clinical use or in late stages of drug development. The mAbs effector mechanisms have been widely analyzed based on in vivo or cell studies. Hereby we intend to complement these functional studies by investigating the mAb-EGFR interactions on a molecular level. Surface plasmon resonance, isothermal titration calorimetry, and static light scattering were employed (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) has become a popular method for protein profiling in clinical diagnosis, as well as in toxicological studies. It combines solid-phase chromatography with TOF-MS on a single platform, which enables the application of crude samples, such as plasma or tissue lysate. In this chapter, we outline two methods that enable the extraction of proteins from tissue samples for subsequent application on ProteinChip (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 The introduction of microarray technology, which is a multiplexed hybridization-based process, allows simultaneous analysis of a large number of nucleic acid transcripts. This massively parallel analysis of a cellular genome will become essential for guiding disease diagnosis and molecular profiling of an individual patient's tumor. Nucleic acid based microarrays can be used for: gene expression profiling, single-nucleotide polymorphisms (SNPs) detection, array-comparative genomic (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 PORTLAND, Ore.-(BUSINESS WIRE)-Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011. Our significant revenue growth resulted from the shipment of the remaining additional one-time orders to Merck Serono and increased sales to Merial. In addition, both operating and net income were positive for the third quarter of 2011 as compared to the negative results of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 GHENT, BELGIUM-(Marketwire - November 09, 2011) - Ablynx [Euronext Brussels: ABLX] today announced that it has further expanded its relationship with Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and entered into a third agreement to co-discover and co-develop Nanobodies() against two targets in osteoarthritis. The companies will exploit the unique Nanobody features and will develop multi-specific products, which have extended half-lives. Under the terms of the agreement, (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8053436 |-| Title: 9-(piperazinylalkyl) carbazoles as bax-modulators |-| Inventors: Halazy; Serge (Vetraz-Monthoux, FR), Church; Dennis (Commugny, CH), Antonsson; Bruno (Billiat, FR), Bombrun; Agnes (Monnetier-Mornex, FR), Gerber; Patrick (Villars-Sous-Yens, CH), Martinou; Jean-Claude (Versonnex, FR) |-| Assignee: Merck Serono SA (Coinsins, CH) |-| The present invention is related to piperazine derivatives of carbazole of formula (I) notably for use as pharmaceutically (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6528a9/neurodegenerative) has announced the addition of the "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth" report to their offering. Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and nine-month periods ended September 30, 2011. Highlights of the third quarter include: We look forward to further revenue growth from our partners going forward. Total net revenues were $4.9 million, compared to $14.2 million for the third quarter of 2010. The 2010 quarter included $8.5 million of the amortization of the $34 million gain on the sale of the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 OBJECTIVE: To evaluate whether features of radiographic hand osteoarthritis (OA) are associated with quantitative magnetic resonance imaging (MRI)-defined knee cartilage thickness, radiographic knee OA, and 1-year structural progression. METHODS: A total of 765 participants in Osteoarthritis Initiative (OAI; 455 women, mean age 62.5 yrs, SD 9.4) obtained hand radiographs (at baseline), knee radiographs (baseline and Year 1), and knee MRI (baseline and Year 1). Hand radiographs were (…) text/html http://www.uspto.gov/ USPTO http://www.lsis.com/channels/?query=4 United States Patent: 8048645 |-| Title: Method of producing functional protein domains |-| Inventors: De Luca; Giampiero (Conches, CH), Falciola; Luca (Geneva, CH) |-| Assignee: Merck Serono SA (Coinsins, Vaud, CH) |-| The present invention provides a method of producing functional protein domains, which are fragments of primary translational products consisting of one or more distinct protein domains encoded by specific subsets of exonic sequences. The method is based on the integration, by (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 28 October 2011 - Biotie Therapies Corp. ("Biotie", NASDAQ-OMX; BTH1V) and Newron Pharmaceuticals S.p.A. ("Newron", SIX; NWRN) have on 27 September 2011 signed a joint merger plan ("Merger Plan") together with a combination agreement for Biotie to acquire Newron through a European Union cross-border merger. On 21 October 2011, Biotie announced that, effective April 2012, Merck Serono will return to Newron the full global rights for safinamide, Newron's lead asset, which is currently in Phase (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 LYON, FRANCE-(Marketwire - October 26, 2011) - Poxel SA today announced that Imeglimin, a novel compound in development for Type 2 diabetes, showed incremental efficacy as an add-on therapy to Metformin, the reference first-line treatment, in patients inadequately controlled by Metformin monotherapy. The study achieved its primary endpoint of superiority in HbA1c reduction versus placebo (p 0.001), and the decrease in FPG (Fasting Plasma Glucose) was also statistically significant (p (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LONDON-(BUSINESS WIRE)-Today, business and health leaders join forces to announce the formation of the ms&work coalition, the first group of its kind to address the needs of people living with Multiple Sclerosis (MS) in the workplace across Europe. The coalition, an alliance of Merck Serono; a leading healthcare company, Microsoft Corp, Employers Forum on Disability (EFD) and the European Federation of Neurological Associations (EFNA) was announced at the 5th Joint Triennial Congress of (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/channels/?query=4 October 21, 2011 - Milan, Italy, October 21, 2011 Newron Pharmaceuticals S.p.A. ( œNewron ), a research and development company focused on novel CNS and pain therapies, announced today that Merck Serono, a division of Merck KGaA, Darmstadt Germany, is returning global rights to safinamide to Newron effective in 180 days. The decision by Merck Serono is due to strategic considerations and re-prioritization of its R&D pipeline, and is not based on any new efficacy or safety findings with (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 BURLINGTON, Mass.-(BUSINESS WIRE)-Decision Resources, one of the world s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade, the Parkinson s disease (PD) drug market will be constrained by generic competition to key therapies. Through 2020, the key PD therapies that will lose patent protection are Novartis/Orion Pharma s Comtan/Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck s Azilect/Agilect, while ropinirole (GlaxoSmithKline s (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/channels/?query=4 SMi's 10th annual Clinical Trials in CNS conference will be an ideal platform for leading industry experts to discover the current and future opportunities within the essential field of CNS drug development. This conference will address current clinical drug discovery activities, as well as innovative and effective drug development strategies and potential problems often faced in clinical trials. This conference will focus on a wide range of therapeutic areas such as Multiple Sclerosis, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX) ranked 447th in Deloitte's prestigious 2011 Technology Fast 500 ¢, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Further, of the 500 nominees from the tri-state area, Columbia ranked in the top 10 percent at number 46. Rankings are based on percentage revenue growth over five years, from 2006-2010; Columbia grew 163 percent during this (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LIVINGSTON, N.J.-(BUSINESS WIRE)-Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Roberto Romero, M.D., chief of the Perinatology Research Branch of the Division of Intramural Research of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), of the National Institutes of Health (NIH), was awarded the 2011 John Dingell Hero for Babies Award by the March of Dimes Michigan Chapter. We congratulate Dr. Romero on this recognition of his (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LYON, France-(BUSINESS WIRE)-Flamel Technologies (Nasdaq: FLML) announced today that it has entered into a multi-year supply agreement with GlaxoSmithKline (NYSE: GSK) for the production of Coreg CR microparticles. Flamel Technologies is the sole supplier of Coreg CR microparticles for GSK. Under the agreement, Flamel will receive guaranteed minimum payments to supply Coreg CR microparticles over a period of several years. The agreement defines the manufacturing relationship between the two (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LYON, France & WOODCLIFF LAKE, N.J.-(BUSINESS WIRE)-Eagle Pharmaceuticals, Inc. and Flamel Technologies SA (NASDAQ: FLML) today announced that the two companies have entered into a license and development agreement for the development of a Medusa-based hydrogel depot formulation of the small molecule antibiotic, tigecycline. Following the promising results generated in the frame of an initial feasibility study established between Flamel and Eagle Pharmaceuticals, Eagle Pharmaceuticals has (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 NEW YORK-(BUSINESS WIRE)-A rarely used and as yet largely unproven approach to drug development has emerged as a significant tool in the effort to create high-impact new cancer drugs. Dual-novel development is expensive and requires more extensive clinical trials than conventional development The technique, described in a just-published paper from the Health & Life Sciences practice of consulting firm Oliver Wyman, is a new twist on the concept of combination drugs. œCombination drugs are (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 ZURICH & DUESSELDORF, Germany-(BUSINESS WIRE)-Promising biotechs will have a unique opportunity to pitch their best assets to a star-studded panel of business development executives in a special competition at BIO-Europe 2011, being held October 31 November 2 at the CCD Congress Center in Duesseldorf, Germany. Thirty seconds is more than enough time to deliver your message In the workshop, œThe Perfect Pitch: Biotech Has Talent,  attendees will have a chance to win a one-to-one meeting (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/channels/?query=4 LAFAYETTE, Colo.-(BUSINESS WIRE)-Aegis Analytical Corp., the leading provider of Manufacturing and Process Intelligence software, announced today that DISCOVER 2011, its annual user conference held Sept. 26-29 in Boulder, Colo., drew more than 80 life sciences industry participants who discussed ways to improve manufacturing quality through IT solutions such as Aegis Discoverant software. Discussions this year related more to quality initiatives and the need for collaboration across global (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/channels/?query=4 Highly concentrated antibody solutions are of increasing importance in the pharmaceutical industry. During production highly concentrated solutions are usually prepared by tangential flow filtration (TFF). Since this technique is often not applicable in the early phase of formulation development, where the available amounts of protein are commonly very small, small scale techniques like dialysis or ultrafiltration with stirred cells or centrifugal filters have to be employed. In this study the (…)